Document:

EX-4.7

 Exhibit 4.7 

[Form of Underwriter’s Warrant Agreement] 

THE REGISTERED HOLDER OF THIS PURCHASE WARRANT, BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE
WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE CLOSING DATE OF
THE OFFERING (DEFINED BELOW) TO ANYONE OTHER THAN (I) NETWORK 1 FINANCIAL SECURITIES, INC. OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE OFFICER OR PARTNER OF NETWORK 1 FINANCIAL SECURITIES,
INC. OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER. 
 THIS PURCHASE WARRANT IS NOT EXERCISABLE PRIOR TO
[                ] [DATE THAT IS SIX MONTHS FROM THE CLOSING DATE OF THE OFFERING]. VOID AFTER 5:00 P.M., EASTERN TIME,
[                ] [DATE THAT IS FIVE YEARS FROM THE CLOSING DATE OF THE OFFERING]. 

COMMON STOCK PURCHASE WARRANT 

For the Purchase of [            ] Shares of Common Stock 

of 
 GENPREX, INC. 

1. Purchase Warrant. THIS CERTIFIES THAT, in consideration of funds duly paid by or on behalf of
             (“Holder”), as registered owner of this Purchase Warrant, to Genprex, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any
time or from time to time from [            ] [DATE THAT IS SIX MONTHS FROM THE CLOSING DATE OF THE OFFERING] (the “Commencement Date”), and at or before 5:00 p.m.,
Eastern time, [            ] [DATE THAT IS FIVE YEARS FROM THE CLOSING DATE OF THE OFFERING] (the “Expiration Date”), but not thereafter, to subscribe for, purchase
and receive, in whole or in part, up to [            ] shares (the “Warrant Shares”) of common stock of the Company, par value $0.001 per share (the
“Shares”), subject to adjustment as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close, then this Purchase Warrant may be exercised on the next succeeding
day which is not such a day in accordance with the terms herein. During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initially exercisable at
$             per Warrant Share (125% of the price of the shares of common stock sold in the proposed initial public offering of Shares (the “Offering”); provided,
however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted by this Purchase Warrant, including the exercise price per Warrant Share and the number of Warrant Shares to be received upon such
exercise, shall be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted exercise price, depending on the context. 

2. Exercise. 

2.1. Exercise Form. In order to exercise this Purchase Warrant, the exercise form attached hereto must be duly executed and
completed and delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Warrant Shares being purchased payable in cash by wire transfer of immediately available funds to an account designated by the
Company or by certified 

 
check or official bank check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time, on the Expiration Date, this Purchase Warrant shall become
and be void without further force or effect, and all rights represented hereby shall cease and expire. 
 2.2. Cashless Exercise. In
lieu of exercising this Purchase Warrant by payment of cash or check payable to the order of the Company pursuant to Section 2.1 above, Holder may elect to receive the number of Warrant Shares equal to the value of this Purchase Warrant (or the
portion thereof being exercised), by surrender of this Purchase Warrant to the Company, together with the exercise form attached hereto, in which event the issue to Holder, Warrant Shares in accordance with the following formula: 

X = Y(A-B)/A 

Where, 
 X = The number of Warrant Shares to be
issued to Holder; 
 Y = The number of Warrant Shares for which the Purchase Warrant is being exercised; 

A = The fair market value of one Share; and 

B = The Exercise Price. 
 For purposes of this
Section 2.2, the fair market value of a Share is defined as follows: 
  

	 	2.2.1.	if the Company’s Common Stock is traded on a securities exchange, the value shall be deemed to be the average of the closing prices of the Shares on such exchange for the five (5) trading day period prior to
the date the exercise form is submitted in connection with the exercise of the Purchase Warrant; 

  

	 	2.2.2.	if the Company’s Common Stock is actively traded over-the-counter, the value shall be deemed to be the average of the closing bid
prices of the Shares for the five (5) trading day period prior to the date the exercise form is submitted in connection with the exercise of the Purchase Warrant; or 

 

	 	2.2.3.	if there is no active public market, the value shall be the fair market value thereof, as determined in good faith by the Company’s Board of Directors. 

2.3. Legend. Each certificate for the securities purchased under this Purchase Warrant shall bear a legend as follows unless such
securities have been registered under the Securities Act of 1933, as amended (the “Securities Act”): 
 “The
securities represented by this certificate have not been registered under the Securities Act of 1933, as amended (the “Act”), or applicable state law. Neither the securities nor any interest therein may be offered for sale, sold or
otherwise transferred except pursuant to an effective registration statement under the Securities Act, or pursuant to an exemption from registration under the Securities Act and applicable state law which, in the opinion of counsel to the Company,
is available.” 
 3. Transfer. 

3.1. General Restrictions. The registered Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such
Holder will not: (a) sell, transfer, assign, pledge or hypothecate this Purchase Warrant for a period of one hundred eighty (180) days following the Effective Date to anyone 

  
 2 

 
other than: (i) to an underwriter or a selected dealer participating in the Offering, or (ii) a bona fide officer or partner of Network 1 Financial Securities, Inc. (“Network
1”) or of any such underwriter or selected dealer, in each case in accordance with FINRA Conduct Rule 5110(g)(1), or (b) cause this Purchase Warrant or the securities issuable hereunder to be the subject of any hedging, short sale,
derivative, put or call transaction that would result in the effective economic disposition of this Purchase Warrant or the securities hereunder, except as provided for in FINRA Rule 5110(g)(2). On and after 180 days after the Effective Date,
transfers to others may be made subject to compliance with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder must deliver to the Company the assignment form attached hereto duly executed and
completed, together with the Purchase Warrant and payment of all transfer taxes, if any, payable in connection therewith. The Company shall within five (5) Business Days transfer this Purchase Warrant on the books of the Company and shall
execute and deliver a new Purchase Warrant or Purchase Warrants of like tenor to the appropriate assignee(s) expressly evidencing the right to purchase the aggregate number of Shares purchasable hereunder or such portion of such number as shall be
contemplated by any such assignment. 
 3.2. Restrictions Imposed by the Securities Act. The securities evidenced by this
Purchase Warrant shall not be transferred unless and until: (i) the Company has received the opinion of counsel for the Holder that the securities may be transferred pursuant to an exemption from registration under the Securities Act and
applicable state securities laws, the availability of which is established to the reasonable satisfaction of the Company (the Company hereby agreeing that the opinion of Magri Law, LLC shall be deemed satisfactory evidence of the availability of an
exemption), or (ii) a registration statement or a post-effective amendment to the Registration Statement relating to the offer and sale of such securities has been filed by the Company and declared effective by the U.S. Securities and Exchange
Commission (the “Commission”) and compliance with applicable state securities law has been established. 
 4. Registration Rights;
Indemnification. 
 4.1. “Piggy-Back” Registration. 

4.1.1. Grant of Right. The Holder shall have the right, for a period of no more than five (5) years from the Closing Date of
the Offering in accordance with FINRA Rule 5110(f)(2)(G)(v), to include all or any portion of the Shares underlying the Purchase Warrants (collectively, the “Registrable Securities”) as part of any other registration of securities
filed by the Company (other than in connection with a transaction contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form); provided, however,
that if, solely in connection with any primary underwritten public offering for the account of the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of shares of Common Stock which
may be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in such
Registration Statement only such limited portion of the Registrable Securities with respect to which the Holder requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable Securities shall be made pro rata
among the Holders seeking to include Registrable Securities in proportion to the number of Registrable Securities sought to be included by such Holders; provided, however, that the Company shall not exclude any Registrable Securities unless the
Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities. 

  
 3 

 4.1.2. Terms. The Company shall bear all fees and expenses attendant to registering
the Registrable Securities pursuant to Section 4.1.1 hereof, but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to represent them in connection with the sale of the
Registrable Securities. In the event of such a proposed registration, the Company shall furnish the then Holders of outstanding Registrable Securities with not less than thirty (30) days written notice prior to the proposed date of filing of
such registration statement. Such notice to the Holders shall continue to be given for each registration statement filed by the Company until such time as all of the Registrable Securities have been sold by the Holder. The holders of the Registrable
Securities shall exercise the “piggy-back” rights provided for herein by giving written notice within ten (10) days of the receipt of the Company’s notice of its intention to file a registration statement. Except as otherwise
provided in this Purchase Warrant, there shall be no limit on the number of times the Holder may request registration under this Section 4.1.2; provided, however, that such registration rights shall terminate on the fifth anniversary of
the Commencement Date. 
 4.2. General Terms. 

4.2.1. Indemnification. The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any
registration statement hereunder and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20 (a) of the Securities Exchange Act of 1934, as amended (“Exchange
Act”), against all loss, claim, damage, expense or liability (including all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which any of them
may become subject under the Securities Act, the Exchange Act or otherwise, arising from such registration statement but only to the same extent and with the same effect as the provisions pursuant to which the Company has agreed to indemnify the
Underwriter contained in Section 5.1 of the Underwriting Agreement between the Underwriter and the Company, dated as of [                    ],
2017. The Holder(s) of the Registrable Securities to be sold pursuant to such registration statement, and their successors and assigns, shall severally, and not jointly, indemnify the Company, against all loss, claim, damage, expense or liability
(including all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending against any claim whatsoever) to which they may become subject under the Securities Act, the Exchange Act or otherwise,
arising from information furnished by or on behalf of such Holders, or their successors or assigns, in writing, for specific inclusion in such registration statement to the same extent and with the same effect as the provisions contained in
Section 5.2 of the Underwriting Agreement pursuant to which the Underwriter have agreed to indemnify the Company. 

4.2.2. Exercise of Purchase Warrants. Nothing contained in this Purchase Warrant shall be construed as requiring the Holder(s) to
exercise their Purchase Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof. 

4.2.3. Documents Delivered to Holders. The Company shall furnish to each Holder participating in any of the foregoing offerings
and to each underwriter of any such offering, if any, a signed counterpart, addressed to such Holder or underwriter, of: (i) an opinion of counsel to the Company, dated the effective date of such registration statement (and, if such
registration includes an underwritten public offering, an opinion dated the date of the closing under any underwriting agreement related thereto), and (ii) a “cold comfort” letter dated the effective date of such registration
statement (and, if such registration includes an underwritten public offering, a letter dated the date of the closing under the underwriting agreement) signed by the independent registered public accounting firm which has issued a report on the
Company’s financial statements included in such registration statement, in 

  
 4 

 
each case covering substantially the same matters with respect to such registration statement (and the prospectus included therein) and, in the case of such accountants’ letter, with respect
to events subsequent to the date of such financial statements, as are customarily covered in opinions of issuer’s counsel and in accountants’ letters delivered to underwriter in underwritten public offerings of securities. The Company
shall also deliver promptly to each Holder participating in the offering requesting the correspondence and memoranda described below and to the managing underwriter, if any, copies of all correspondence between the Commission and the Company, its
counsel or auditors and all memoranda relating to discussions with the Commission or its staff with respect to the registration statement and permit each Holder and underwriter to do such investigation, upon reasonable advance notice, with respect
to information contained in or omitted from the registration statement as it deems reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access to books, records and properties and
opportunities to discuss the business of the Company with its officers and independent auditors, all to such reasonable extent and at such reasonable times as any such Holder shall reasonably request. 

4.2.4. Underwriting Agreement. In the event the Company shall enter into an underwriting agreement with the managing
underwriter(s), if any, selected by the Company with respect to the Registrable Securities that are being registered pursuant to this Section 4, which managing underwriter shall be reasonably satisfactory to the Holders of a majority of the
Registrable Securities. Such agreement shall be reasonably satisfactory in form and substance to the Company, the Holders of a majority of the Registrable Securities and such managing underwriter, and shall contain such representations, warranties
and covenants by the Company and such other terms as are customarily contained in agreements of that type used by the managing underwriter. The Holders shall be parties to any underwriting agreement relating to an underwritten sale of their
Registrable Securities and may, at their option, require that any or all the representations, warranties and covenants of the Company to or for the benefit of such underwriter shall also be made to and for the benefit of such Holders. Such Holders
shall not be required to make any representations or warranties to or agreements with the Company or the underwriter except as they may relate to such Holders, their Shares and their intended methods of distribution. 

4.2.5. Documents to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish
to the Company a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders. 

4.2.6. Damages. Should the registration or the effectiveness thereof required by Section 4.1 hereof be delayed by the Company
or the Company otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to the Holder(s), be entitled to seek specific performance or other equitable (including injunctive) relief
against the threatened breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and without the necessity of posting bond or other security. 

5. New Purchase Warrants to be Issued. 

5.1. Partial Exercise or Transfer. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or
assigned in whole or in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation, together with the duly executed exercise or assignment form and funds sufficient to pay any
Exercise Price and/or transfer tax if exercised pursuant to Section 2.1 hereto, the Company shall cause to be delivered to the Holder without charge a new Purchase Warrant of like tenor to this Purchase Warrant in the name of the Holder
evidencing the right of the Holder to purchase the number of Shares purchasable hereunder as to which this Purchase Warrant has not been exercised or assigned. 

  
 5 

 5.2. Lost Warrant. Upon receipt by the Company of evidence satisfactory to it of the
loss, theft, destruction or mutilation of this Purchase Warrant and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new Purchase Warrant of like tenor and date. Any such new Purchase
Warrant executed and delivered as a result of such loss, theft, mutilation or destruction shall constitute a substitute contractual obligation on the part of the Company. 

6. Adjustments. 

6.1. Adjustments to Exercise Price and Number of Securities. The Exercise Price and the number of Shares underlying the Purchase
Warrant shall be subject to adjustment from time to time as hereinafter set forth: 
 6.1.1. Share Dividends; Split Ups. If,
after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding Shares is increased by a stock dividend payable in Shares or by a split up of Shares or other similar event, then, on the effective day
thereof, the number of Shares purchasable hereunder shall be increased in proportion to such increase in outstanding Shares, and the Exercise Price shall be proportionately decreased. 

6.1.2. Aggregation of Shares. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of
outstanding Shares is decreased by a consolidation, combination or reclassification of Shares or other similar event, then, on the effective date thereof, the number of Shares purchasable hereunder shall be decreased in proportion to such decrease
in outstanding Shares, and the Exercise Price shall be proportionately increased. 
 6.1.3. Replacement of Securities upon
Reorganization, etc. In case of any reclassification or reorganization of the outstanding Shares other than a change covered by Section 6.1.1 or 6.1.2 hereof or a change that solely affects the par value of such Shares, or in the case of
any share reconstruction or amalgamation or consolidation of the Company with or into another corporation (other than a consolidation or share reconstruction or amalgamation in which the Company is the continuing corporation and that does not result
in any reclassification or reorganization of the outstanding Shares), the Holder of this Purchase Warrant shall have the right thereafter (until the expiration of the right of exercise of this Purchase Warrant) to receive upon the exercise hereof,
for the same aggregate Exercise Price payable hereunder immediately prior to such event, the kind and amount of shares of stock or other securities or property (including cash) receivable upon such reclassification, reorganization, share
reconstruction or amalgamation, or consolidation, by a Holder of the number of Shares of the Company obtainable upon exercise of this Purchase Warrant immediately prior to such event; and if any reclassification also results in a change in Shares
covered by Section 6.1.1 or 6.1.2, then such adjustment shall be made pursuant to Sections 6.1.1, 6.1.2 and this Section 6.1.3. The provisions of this Section 6.1.3 shall similarly apply to successive such reclassifications,
reorganizations, share reconstructions or amalgamations, or consolidations, sales or other transfers. 
 6.1.4. Changes in Form of
Purchase Warrant. This form of Purchase Warrant need not be changed because of any change pursuant to this Section 6.1, and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Warrant Shares
as are stated in the Purchase Warrants initially issued pursuant to this Agreement. The acceptance by any Holder of the issuance of new Purchase Warrants reflecting a required or permissive change shall not be deemed to waive any rights to an
adjustment occurring after the Commencement Date or the computation thereof. 

  
 6 

 6.2. Substitute Purchase Warrant. In case of any consolidation of the Company with,
or share reconstruction or amalgamation of the Company with or into, another corporation (other than a consolidation or share reconstruction or amalgamation which does not result in any reclassification or change of the outstanding Shares), the
corporation formed by such consolidation or share reconstruction or amalgamation shall execute and deliver to the Holder a supplemental Purchase Warrant providing that the holder of each Purchase Warrant then outstanding or to be outstanding shall
have the right thereafter (until the stated expiration of such Purchase Warrant) to receive, upon exercise of such Purchase Warrant, the kind and amount of shares of stock and other securities and property receivable upon such consolidation or share
reconstruction or amalgamation, by a holder of the number of Shares of the Company for which such Purchase Warrant might have been exercised immediately prior to such consolidation, share reconstruction or amalgamation, sale or transfer. Such
supplemental Purchase Warrant shall provide for adjustments which shall be identical to the adjustments provided for in this Section 6. The above provision of this Section shall similarly apply to successive consolidations or share
reconstructions or amalgamations. 
 6.3. Elimination of Fractional Interests. The Company shall not be required to issue
certificates representing fractions of Shares upon the exercise of the Purchase Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being the intent of the parties that all fractional interests shall
be eliminated by rounding any fraction up or down, as the case may be, to the nearest whole number of Shares or other securities, properties or rights. 

7. Reservation and Listing. The Company shall at all times reserve and keep available out of its authorized Shares, solely for the purpose of
issuance upon exercise of the Purchase Warrants, such number of Shares or other securities, properties or rights as shall be issuable upon the exercise thereof. The Company covenants and agrees that, upon exercise of the Purchase Warrants and
payment of the Exercise Price therefor, in accordance with the terms hereof, all Shares and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable and not
subject to preemptive rights of any shareholder. As long as the Purchase Warrants shall be outstanding, the Company shall use its commercially reasonable efforts to cause all Shares issuable upon exercise of the Purchase Warrants to be listed
(subject to official notice of issuance) on the Nasdaq Capital Market or any other market on which the Shares issued to the public in the Offering may then be listed and/or quoted. 

8. Certain Notice Requirements. 

8.1. Holder’s Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holders the right to vote or
consent or to receive notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder of the Company. If, however, at any time prior to the expiration of the Purchase Warrants and their
exercise, any of the events described in Section 8.2 shall occur, then, in one or more of said events, the Company shall give written notice of such event at least fifteen days prior to the date fixed as a record date or the date of closing the
transfer books for the determination of the shareholders entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled to vote on such proposed dissolution, liquidation, winding up or sale. Such
notice shall specify such record date or the date of the closing of the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver to each Holder a copy of each notice given to the other shareholders of the Company
at the same time and in the same manner that such notice is given to the shareholders. 

  
 7 

 8.2. Events Requiring Notice. The Company shall be required to give the notice
described in this Section 8 upon one or more of the following events: (i) if the Company shall take a record of the holders of its Shares for the purpose of entitling them to receive a dividend or distribution payable otherwise than in
cash, or a cash dividend or distribution payable otherwise than out of retained earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company, (ii) the Company shall offer to all the holders of
its Shares any additional shares of capital stock of the Company or securities convertible into or exchangeable for shares of capital stock of the Company, or any option, right or warrant to subscribe therefor, or (iii) a dissolution,
liquidation or winding up of the Company (other than in connection with a consolidation or share reconstruction or amalgamation) or a sale of all or substantially all of its property, assets and business shall be proposed. 

8.3. Notice of Change in Exercise Price. The Company shall, promptly after an event requiring a change in the Exercise Price
pursuant to Section 6 hereof, send notice to the Holders of such event and change (“Price Notice”). The Price Notice shall describe the event causing the change and the method of calculating same and shall be certified as being
true and accurate by the Company’s Chief Financial Officer. 
 8.4. Transmittal of Notices. All notices, requests, consents
and other communications under this Purchase Warrant shall be in writing and shall be deemed to have been duly made when hand delivered, or mailed by express mail or private courier service: (i) if to the registered Holder of the Purchase
Warrant, to the address of such Holder as shown on the books of the Company, or (ii) if to the Company, to following address or to such other address as the Company may designate by notice to the Holders: 

If to the Holder: 

Network 1 Financial Securities, Inc. 

Galleria, Penthouse 
 2 Bridge
Avenue, Building 2 
 Red Bank, NJ 07701 

Attn: Damon D. Testaverde, Director of Investment Banking 

Fax No.: (732) 758-6671 

With a copy (which shall not constitute notice) to: 

Magri Law, LLC 
 2642 NE 9th Ave. 
 Fort Lauderdale, FL 33334 

Attn: Philip Magri 
 Email:
pmagri@magrilaw.com 
 Fax No.: 646-836-9200 

If to the Company: 

Genprex, Inc. 
 100 Congress
Avenue, Suite 2000 

  
 8 

 Austin, Texas 78701 

Attn: J. Rodney Varner 
 Chief
Executive Officer 
 With a copy (which shall not constitute notice) to: 

Streusand Landon & Ozburn, LLP 

811 Barton Springs Road, Suite 811 

Austin, TX 78704 
 Attn:
Christopher J. Ozburn 
 Fax: (512) 236-9904 

9. Miscellaneous. 

9.1. Amendments. The Company and Network 1 may from time to time supplement or amend this Purchase Warrant without the
approval of any of the Holders in order to cure any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent with any other provisions herein, or to make any other provisions in regard to matters or
questions arising hereunder that the Company and Network 1 may deem necessary or desirable and that the Company and Network 1 deem shall not adversely affect the interest of the Holders. All other modifications or amendments shall require the
written consent of and be signed by the party against whom enforcement of the modification or amendment is sought. 

9.2. Headings. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit
or affect the meaning or interpretation of any of the terms or provisions of this Purchase Warrant. 
 9.3. Entire Agreement.
This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and
supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof. 

9.4. Binding Effect. This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the
Company and their permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase
Warrant or any provisions herein contained. 
 9.5. Governing Law; Submission to Jurisdiction; Trial by Jury. This Purchase
Warrant shall be governed by and construed and enforced in accordance with the laws of the State of Texas, without giving effect to conflict of laws principles thereof. The Company hereby agrees that any action, proceeding or claim against it
arising out of, or relating in any way to this Purchase Warrant shall be brought and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New York, and irrevocably submits to
such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any process or summons to be served upon the Company may be served
by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to it at the address set forth in Section 8 hereof. Such 

  
 9 

 
mailing shall be deemed personal service and shall be legal and binding upon the Company in any action, proceeding or claim. The Company and the Holder agree that the prevailing party(ies) in any
such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on its behalf
and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and the Holder hereby irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding
arising out of or relating to this Agreement or the transactions contemplated hereby. 
 9.6. Waiver, etc. The failure of the
Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or any provision hereof
or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase Warrant. No waiver of any breach, non-compliance or
non-fulfillment of any of the provisions of this Purchase Warrant shall be effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver
is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance or non-fulfillment. 
 9.7. Execution in
Counterparts. This Purchase Warrant may be executed in two or more counterparts, and by the different parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one
and the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and delivered to each of the other parties hereto. Such counterparts may be delivered by facsimile transmission or other
electronic transmission. 
 9.8. Exchange Agreement. As a condition of the Holder’s receipt and acceptance of this Purchase
Warrant, Holder agrees that, at any time prior to the complete exercise of this Purchase Warrant by Holder, if the Company and Network 1 enter into an agreement (“Exchange Agreement”) pursuant to which they agree that all
outstanding Purchase Warrants will be exchanged for securities or cash or a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement. 

[Signature Page Follows] 

  
 10 

 IN WITNESS WHEREOF, the Company has caused this Purchase Warrant to be signed by its duly authorized officer as
of the         day of                     , 2017. 

GENPREX, INC. 
  

	
	 By:
                                         
        

	 Name: J. Rodney Varner

	 Title: Chief Executive Officer

  
 11 

 [Form to be used to exercise Purchase Warrant] 

Date:                     ,
20         
 The undersigned hereby elects irrevocably to exercise the Purchase Warrant
for             shares of common stock, par value $0.001 per share (the “Shares”), of Genprex, Inc., a Delaware corporation (the “Company”), and hereby
makes payment of $             (at the rate of $             per Share) in payment of the Exercise Price pursuant thereto. Please
issue the Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been exercised. 

or 
 The undersigned hereby elects irrevocably to convert its
right to purchase             Shares of the Company under the Purchase Warrant for             Shares, as determined in
accordance with the following formula: 
 X = Y(A-B)/A 

Where, 
 X = The number of Shares to be issued to
Holder; 
 Y = The number of Shares for which the Purchase Warrant is being exercised; 

A = The fair market value of one Share which is equal to $            ; and 

B = The Exercise Price which is equal to $             per share 

The undersigned agrees and acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement with respect to
the calculation shall be resolved by the Company in its sole discretion. 
 Please issue the Shares as to which this Purchase Warrant is exercised in
accordance with the instructions given below and, if applicable, a new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been converted. 

 

	
	
Signature                 
                                         
                     

	
	 Signature
Guaranteed                                       
                 

  
 12 

 INSTRUCTIONS FOR REGISTRATION OF SECURITIES: 

 

			
	Name:	 	  

		 	(Print in Block Letters)
		
	Address:        	 	  

		
		 	  

		
		 	  

 NOTICE: The signature to this form must correspond with the name as written upon the face of the Purchase Warrant without
alteration or enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities exchange. 

  
 13 

 [Form to be used to assign Purchase Warrant] 

ASSIGNMENT 
 (To be executed
by the registered Holder to effect a transfer of the within Purchase Warrant): 
 FOR VALUE
RECEIVED,                     does hereby sell, assign and transfer unto the right to purchase shares of common stock, par value $0.001 per
share, of Genprex, Inc., a Delaware corporation (the “Company”), evidenced by the Purchase Warrant and does hereby authorize the Company to transfer such right on the books of the Company. 

 

	
	 Dated:
                    , 20        

	
	
Signature                 
                                         
                     

	
	 Signature
Guaranteed                                       
                 

 NOTICE: The signature to this form must correspond with the name as written upon the face of the within Purchase
Warrant without alteration or enlargement or any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national securities exchange. 

  
 14EX-10.14

 Exhibit 10.14 

CLINICAL STUDY AGREEMENT 

THIS Agreement is made and entered into this 10th day of February, 2014 (“Effective
Date”), by and between The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 (“MD Anderson”), a member institution of The University of Texas System (“System”), and
Genprex, Inc., (“Sponsor”), for purposes of confirming the parties intent and agreement to conduct a clinical study and evaluation as set forth herein. Accordingly, MD Anderson and Sponsor agree as follows: 

RECITALS 
 WHEREAS, Sponsor was formerly
known as “Convergen Lifesciences, Inc.” and legally changed its name to Genprex, Inc.; 
 WHEREAS, MD Anderson conducted a clinical study entitled
“Phase I Study of Intravenous DOTAP: Cholestrol-fus1 Nanoparticle Complex (DOTAP:Chol-fus1) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Chemotherapy” (the “Phase I Clinical Study”); 

WHEREAS, the Phase I Clinical Study was the subject of an Investigational New Drug application 10718 (the “IND”) with the Food and Drug
Administration (the “FDA”), held by MD Anderson as sponsor of the Phase I Clinical Study; 
 WHEREAS, pursuant to the IND Transfer and Data Use
Agreement dated October 14, 2013, MD Anderson has transferred and Sponsor has assumed ownership of the IND by taking over as the sponsor as defined in 21 C.F.R. § 312.3; 

WHEREAS, Sponsor and its predecessors in interest funded research conducted at MD Anderson pursuant to a Sponsored Research Agreement dated September 14,
2010 (hereinafter referred to as “Funding Agreement”); with Dr. Reza Mehran continuing as the project director and steward for the funding provided under the Funding Agreement and for the clinical trial agreement “Phase I/II
Clinical Trial Combining FUS1-Nanoparticles and Erlotinib in Stage IV Lung Cancers” SRA and continued through the five year effective date of this Agreement. 

WHEREAS, MD Anderson desires to perform a clinical trial entitled “Phase I/II Clinical Trial combining FUS1-Nanoparticles and Erlotinib in Stage IV Lung
Cancer” (“Study”) under the supervision of Dr. Charles Lu (“Principal Investigator”) using certain funds received under the Funding Agreement; 

WHEREAS, Sponsor is willing to provide TUSC2 pDNA and other materials to MD Anderson at no cost (“Materials”) as necessary for conduct of the Study.

 NOW, THEREFORE, in consideration of delivery of Materials by Sponsor, and the representations, warranties and
covenants of each party to the other made herein, the parties hereto agree as follows: 
 1. PROTOCOL 

1.1 MD Anderson agrees to conduct the Study, as described in Exhibit A (“Protocol”), attached hereto for reference purposes only. The Study
will be supervised by Principal Investigator at MD Anderson, with assistance from associates and colleagues as required. 
 1.2 Sponsor agrees to provide at
no cost to MD Anderson Materials in sufficient quantities to conduct the Study. MD Anderson shall combine Materials with DOTAP to generate CNVN202, also known as Oncoprex (“Study Drug”). 

1.3 Nothing in this Agreement will limit or prohibit MD Anderson or any of its personnel, including the Principal Investigator, from conducting any research
or for performing research for or with any entity or person, including any other outside sponsors. 
 1.4 Notwithstanding anything herein, the parties agree
that the Study will be conducted in accordance with the Protocol, applicable laws and regulations, and MD Anderson’s institutional policies and standards. MD Anderson and Sponsor will promptly notify each other upon identifying any aspect of
the Protocol, information discovered during monitoring visits, and/or Study Data (as hereinafter defined) that may adversely affect the safety, well-being, or medical care of Study subjects, or that may affect the willingness of subjects to continue
participation of the Study, influence the conduct of the Study, or that may alter IRB approval to continue the Study. When possible, such findings shall be submitted to MD Anderson electronically. MD Anderson shall promptly notify the IRB of any
such events. When Study subject safety or medical care could be directly affected by Study Data, then notwithstanding any other provision of this Agreement, MD Anderson will send Study subjects a written communication about Study Data. 

1.5 If a Study Subject suffers injury as a direct result of taking part in this Study, MD Anderson health providers will provide medical care. However, this
medical care will be billed to the Study Subject’s insurance provider, or to the Study Subject, in the ordinary manner. 
 1.6 Sponsor and MD Anderson
will promptly notify each other upon identifying any aspect of the Protocol, including information discovered during site monitoring visits, or the Study results that may adversely affect the safety, well-being, or medical care of Study subjects, or
that may affect the willingness of subjects to continue participation of the Study, influence the conduct of the Study, or that may alter the IRB approval to continue the Study, when possible, such findings shall be submitted to MD Anderson
electronically. MD Anderson shall promptly notify the IRB of any such events. When Study subject safety or medical care could be directly affected by the Study results, then notwithstanding any other provision of this Agreement, MD Anderson will
send Study subjects a written communication about the Study results. 

  
 2 

 2. IND & MONITORING 

 

	2.1	The Study shall be conducted under Sponsor’s IND with Sponsor as the “sponsor” as defined in 21 C.F.R. § 312.3. 

2.2. To the extent necessary for Sponsor to perform its regulatory duties as IND Study sponsor, during the term of this Agreement and for one (1) year
thereafter , MD Anderson shall permit Sponsor and/or its authorized representatives to conduct periodic monitoring visits, at mutually acceptable times during normal administrative business hours, to inspect and examine MD Anderson’s facilities
at which the Study is being conducted, including inspecting and examining Study Data and Study records to verify Principal Investigator and MD Anderson’s compliance with the terms and conditions of this Agreement and the Protocol. MD Anderson
and Principal Investigator shall cooperate with Sponsor and/or its representatives during such periodic monitoring visits. Sponsor’s rights in this Section 2.2 shall be subject to Sponsor’s compliance with MD Anderson’s
reasonable measures for purposes of confidentiality, safety, and security, and will be further subject to Sponsor’s compliance with MD Anderson’s premises rules that are generally applicable to all persons at MD Anderson’s
facilities. Should Sponsor utilize one or more third party(s) in exercising its rights in this paragraph, Sponsor certifies that such party(s) shall be subject to an obligation of confidentiality consistent with the obligations of
confidentiality required of Sponsor hereunder and such third party(s) shall be subject to any and all conditions upon Sponsor’s rights that are set forth in this Section. If Sponsor obtains, learns of, comes in contact with, or otherwise
has access to any patient health and medical information, Sponsor will keep such information confidential and will comply with all applicable laws regarding the confidentiality of such information and Sponsor will not use or disclose such patient
health and medical information in a manner that would violate any applicable law (including the HIPAA Privacy Regulations) if such use or disclosure were made by MD Anderson. 

2.3 Notwithstanding anything to the contrary herein, Sponsor agrees that MD Anderson shall retain the right to cross-file on the IND and its contents in any
new investigational new drug application or clinical study that may be filed by MD Anderson with FDA with respect to technology utilizing the FUS1/TUSC2 genes that is exclusively licensed from MD Anderson to Sponsor. 

3. TERM 
 3.1 This Agreement is effective
as of the Effective Date and shall continue in force until the earlier of completion of the Study as mutually agreed upon by the parties or five (5) years from the Effective Date, unless earlier terminated in accordance with this Agreement.

 3.2. This Agreement may be terminated: (a) immediately by the written agreement of both parties; (b) immediately upon written notice by MD
Anderson if at any time Principal Investigator is unable to continue to serve and the parties cannot agree upon a mutually acceptable successor to Principal Investigator; or (c) immediately upon written notice by either party if necessary for
the safety, health, or welfare of Study subjects. In addition, Sponsor may terminate this Agreement upon thirty (30) days prior written notice to MD Anderson with due regard for subject health and safety. 

3.3 Upon the expiration or early termination of this Agreement, Sponsor shall have thirty (30) days from the date of such expiration or termination to
have any remaining Materials removed from MD Anderson’s premises. If Sponsor fails to remove the remaining Materials with such time period, then MD Anderson may destroy any remaining Materials in accordance with MD Anderson’s institutional
policies. 

  
 3 

 4. INDEMNIFICATION 

4.1 Sponsor shall indemnify and hold harmless MD Anderson, System, their Regents, officers, agents and employees from liability, loss, and expense resulting
from judgments or claims against them arising out of (a) the performance of the Study in accordance with the protocol, and (b) the use by Sponsor of Study Data; provided, however, that Sponsor shall not be obligated to indemnify or hold MD
Anderson harmless from claims arising from or related to the negligence or willful misconduct of MD Anderson, its officers, agents, or employees. 
 4.2 To
the extent authorized under the constitution and laws of the State of Texas, MD Anderson shall indemnify and hold harmless Sponsor from liability, loss, and expense resulting from the negligent acts or omissions of MD Anderson in its performance of
the Study; provided, however, that MD Anderson shall not indemnify or hold Sponsor harmless from claims arising from or related to the negligence or willful misconduct of Sponsor, its officers, agents, or employees, or any person or entity not
subject to MD Anderson’s supervision or control. 
 5. STUDY DATA 

5.1 MD Anderson shall own all data and results generated in the performance of the Study, (“Study Data”), and shall have the right to use
such Study Data only for (i) its internal academic, non-commercial research and patient care purposes, and (ii) to publish the Study Data in accordance with Section 6 hereunder. For clarity, other than publications made in accordance
with Section 6, MD Anderson shall not publicly disclose unpublished Study Data to third parties except for members of its scientific or institutional review boards, provided, however, that such persons are obligated to maintain the
confidentiality of such information consistent with the terms of this Agreement. Once Study Data has been publicly disclosed, the parties may use the publicly disclosed Study Data for any purpose. MD Anderson will, from time to time, upon
Sponsor’s reasonable request promptly provide the de-identified Study Data to Sponsor in the form of an interim report, provided, however, Sponsor shall hold such information in confidence until the earlier of (a) publication or public
disclosure of such information by MD Anderson and/or Principal Investigator in accordance with this Agreement; or (b) twelve months following completion of the Study; provided, however, Sponsor may (to the extent necessary for Sponsor to
perform its regulatory duties as IND Study sponsor) disclose Study Data to FDA and other regulatory authorities, and to its bonafide current or prospective advisors, investors, partners and collaborators who have agreed to maintain the
confidentiality of the Study Data under a separate confidentiality agreement at least as protective of MD Anderson’s rights as the terms of this Agreement. Sponsor shall be liable for breach of such confidentiality agreement by its bonafide
current and prospective advisors, investors, business partners and collaborators. To the extent any results Study Data includes Protected Health Information (as such term is defined by HIPAA), Sponsor shall only use such Protected Health Information
in accordance with the informed consent and the authorization document. 
 5.2 MD Anderson shall also provide to Sponsor a final Study report within a
reasonable time after completion of the Study. Sponsor shall keep the Study report confidential until the earlier of (a) publication or other public presentation of such Study report by MD Anderson, or (b) twelve (12) months after the
completion of the Study 

  
 4 

 6. PUBLICATION 

6.1 MD Anderson shall have the first right to publish or otherwise make public Study Data provided that MD Anderson shall first submit any such publication or
public disclosure of Study Data to Sponsor for review and comment at least thirty (30) days prior to submission for publication or release. Sponsor shall have thirty (30) days from receipt to review and provide written comments to MD
Anderson. MD Anderson shall review such comments in good faith. Notwithstanding anything to the contrary, MD Anderson has the right to register the Study in a manner consistent with the requirements of applicable law and the International Committee
of Medical Journal Editors (i.e. register the Study on clinical trial public registries and post Study Data on such public registries). 
 6.2 Except as
otherwise provided herein, or as required by law or regulation or to the extent necessary for purposes of publishing or presenting the Study Data, neither party shall release or distribute any materials or information containing the name of the
other party or any of its employees without prior written approval by an authorized representative of the non-releasing party. Sponsor has the right to disclose the existence and general nature of this Agreement without MD Anderson’s approval
as required by applicable law or regulation; and Sponsor may disclose the terms of this Agreement to its bonafide current and prospective advisors, investors, business partners and collaborators who have agreed to maintain the confidentiality of
such terms under a separate confidentiality agreement at least as protective of MD Anderson’s rights as the terms of this Agreement. Sponsor shall be liable for breach of such confidentiality agreement by its bonafide current and prospective
advisors, investors, business partners and collaborators. 
 7. CONFIDENTIALITY 

7.1 The parties may disclose confidential information to each other in connection with the Study and during the term of this Agreement (“Confidential
Information”). Each party will use Confidential Information of the other party only to the extent required to conduct the Study, and will use reasonable efforts to prevent the disclosure of any of the other party’s Confidential
Information to third parties for a period of five (5) years after disclosure of such Confidential Information, provided that the receiving party’s obligation shall not apply to information that: (a) is already in the receiving
party’s possession at the time of disclosure by the disclosing party; (b) is or later becomes part of the public domain through no fault of the receiving party; (c) is received from a third party having no obligations of
confidentiality to the disclosing party; (d) is independently developed by the receiving party; (e) is required by law or regulation to be disclosed; (f) is communicated to the receiving party’s IRB or other scientific committee
provided, however, that such persons are obligated to maintain the confidentiality of such information consistent with the terms of this Agreement; (g) is required to be disclosed in order to obtain informed consent from potential Study
subjects, provided, however, that the information will be disclosed only to the extent necessary and Confidential Information will not be provided in answer to unsolicited inquiries by telephone or to individuals who are not eligible Study subjects;
or (h) is disclosed to a Study subject for the safety or well-being of the Study subject. 
 In the event that receiving party is required to disclose
information pursuant to Section 7.1(e), the receiving party shall, to the extent practicable, notify the disclosing party to allow the disclosing party to assert whatever exclusions or exemptions may be available to it under such law or
regulation. 

  
 5 

 7.2 Notwithstanding anything to the contrary, if and when Confidential Information is subject to one of the
exclusions mentioned above or is no longer confidential as a result of an authorized disclosure of such information under the terms of this Agreement, including any publication in accordance with Section 6.1, then the receiving party will not
have any restriction upon its use or disclosure of such information. 
 7.3 In the event that Sponsor shall come into contact with any “Protected
Health Information” (as such term is defined under HIPAA) of MD Anderson or any information which could be used to identify any of MD Anderson’s patients or research subjects, Sponsor shall maintain any such Protected Health Information or
other such information confidential in accordance with laws and regulations as applicable to MD Anderson, including without limitation HIPAA, and shall not use or disclose any such Protected Health Information or other information except as
authorized by applicable law and by the applicable subject’s informed consent/authorization documents, or in any manner that would constitute a violation of any applicable law or regulation if such use or disclosure was made by MD Anderson.

 8. INTELLECTUAL PROPERTY RIGHTS 
 8.1
Any invention, discovery, concept, or idea, whether or not patentable, conceived of and first reduced to practice during the conduct of the Study, and arising from the performance of the Study (“Invention”) shall be owned as
determined on the basis of inventorship which shall be determined in accordance with United States patent law. For clarification purposes, the term “Invention” under this Agreement shall not reach to inventions, discoveries, concepts, or
ideas arising from the Phase I Clinical Study, the Funding Agreement, or from any other agreements or projects of the parties. 
 8.2 MD Anderson will
promptly disclose to Sponsor any Invention by MD Anderson after notice of such Invention is received by MD Anderson’s Office of Technology Commercialization. All information relating to Inventions shall be deemed to be Confidential Information
of MD Anderson under Section 7.1 above and shall be held in confidence by Sponsor. 
 8.3 MD Anderson hereby grants to Sponsor an exclusive option to
negotiate an exclusive (subject to MD Anderson’s right to use such Inventions for internal research, academic, and patient care purposes) or non-exclusive, worldwide, royalty-bearing license to any Invention in which MD Anderson has an
ownership interest, provided that Sponsor pays all patent expenses for such Invention in the event Sponsor exercises its option. Sponsor shall exercise its option to negotiate a license to any Invention by notifying MD Anderson in writing within
thirty (30) days of MD Anderson disclosing such Invention to Sponsor (“Option Period”). If Sponsor fails to timely exercise its option within the Option Period with respect to any Invention, Sponsor’s right to license such
Invention shall terminate, and MD Anderson shall be free to license such Invention to any other party with no further obligation to Sponsor. If Sponsor timely exercises its option, the terms of the license shall be negotiated in good faith within
ninety (90) days of the date such option is exercised, or within such time as the parties may mutually agree in writing (“Negotiation Period”). If, however, Sponsor timely exercises its option, but MD Anderson and Sponsor are
unable to agree upon the terms of the license during the Negotiation Period, Sponsor’s rights to license such Invention shall terminate, and MD Anderson shall be free to license such Invention to any other party with no further obligation to
Sponsor. MD Anderson shall not be obligated to file a patent application for any Invention in which it has an ownership interest, but MD Anderson agrees to file all patent applications for Inventions requested by Sponsor, provided Sponsor pays all
such patent expenses for such Invention using patent counsel acceptable to Sponsor and MD Anderson. 

  
 6 

 8.4 Sponsor grants MD Anderson the right to use Materials solely for the conduct of the Study. With the exception
of the foregoing, nothing contained in this Agreement shall be deemed to grant any license to any party under any patents, patent applications, or other intellectual property or proprietary interests in or to any other inventions, discovery or
improvement of the other party (“Background Intellectual Property”), except that Sponsor grants MD Anderson a limited license to any Sponsor Background Intellectual Property necessary for conducting the Study. 

8.5 Notwithstanding anything to the contrary, to the extent that MD Anderson uses any U.S. Government funding or support in conducting the Study, the U.S.
Government may obtain certain rights and interest in some Inventions, and that this Agreement is subject to any such U. S. Governmental rights and interests. 

9. STUDY DRUG 
 9.1 Sponsor represents and
warrants that it owns or controls patents and/or licenses covering methods of use and composition of Study Drug (FUS1+DOTAP) including each component thereof and the combination thereof (“Technology Rights”) to be used in the Study.
Sponsor hereby grants MD Anderson the right to manufacture, use and practice Technology Rights for performance of the Study. SPONSOR represents and warrants that it has the right to grant Technology Rights and that such grant will not infringe any
third party rights. Sponsor shall provide, for no charge, reasonably sufficient quantities of Materials to MD Anderson for MD Anderson to generate the final version of the Study Drug for use in the Study. Materials shall remain the sole property of
Sponsor and be used by MD Anderson solely for purposes of conducting the Study (and not for any other study or purpose). MD Anderson shall retain control over the Materials and Study Drug and not transfer the same to a third party without
Sponsor’s express prior written approval. Study Drug shall be used by MD Anderson solely for purposes of conducting the Study (and not for any other study or purpose). 

9.2 MD Anderson shall generate the final version of the Study Drug in accordance all applicable laws. In connection with the foregoing, MD Anderson shall
generate and maintain complete and accurate records and samples in accordance with applicable laws, including batch and lot records and samples, quality control and laboratory testing, and any other data required by applicable laws. All such records
and samples shall be maintained for such periods as may be required by applicable law; provided that prior to destroying or otherwise disposing of any such records or samples, MD Anderson shall provide Sponsor prior written notice thereof and
discuss the [possibility] of Sponsor taking possession of such records at Sponsor’s own expense. In addition, to the extent required by applicable law and/or regulation for Sponsor to comply with its regulatory obligations as
“sponsor” of the Study in connection with the IND, MD Anderson agrees, upon Sponsor’s reasonable request from time to time and at Sponsor’s expense, to provide Sponsor with documentation describing the procedures, methods and
processes used in connection with the generation of the final version of the Study Drug for the Study hereunder, and Sponsor may only use such documentation for purposes of complying with applicable law and/or regulation to fulfill its regulatory
obligations as “sponsor” of the Study in connection with the IND and related applications for marketing approval, and for no other purpose. Upon reasonable request by Sponsor from time to time and at Sponsor’s expense and at mutually
agreed times and places, MD Anderson shall, to the extent practicable, provide reasonable cooperation and assistance to Sponsor or its designee to understand all such documentation, but only to the extent required by applicable law and/or regulation
for Sponsor to comply with its regulatory obligations as “sponsor” of the Study in connection with the IND and related applications for marketing approval. 

  
 7 

 9.3 MD Anderson and Principal Investigator shall permit only subjects under Principal Investigator’s
supervision as part of the Study to receive the Study Drug and shall not deliver the Study Drug to any third party without the prior written approval of Sponsor. 

9.4 MD Anderson represents and certifies to Sponsor that the final version of the Study Drug generated by MD Anderson hereunder shall have been generated in
accordance with all applicable laws, and MD Anderson shall perform and document all manufacturing activities contemplated herein in compliance with all applicable laws. 

10. GENERAL 
 10.1 This Agreement,
including the attached Exhibit A, constitutes the entire and only agreement between the parties relating to the Study, and all prior negotiations, representations, agreements, and understandings are superseded hereby. No agreements altering or
supplementing the terms hereof, including the attached Exhibit A, may be made except by a written document signed by the duly authorized representatives of the parties. The parties agree that nothing in this agreement shall affect any other
agreements or licenses entered into by the Parties. 
 10.2 Any conflicts or inconsistencies between the Protocol and this Agreement shall be governed and
controlled by this Agreement. 
 10.3 MD Anderson will not be liable for any failure to perform as required by this Agreement, if the failure to perform is
caused by occurrences beyond its control, including but not limited to acts of God, embargoes, governmental restrictions, strikes or other concerted acts of workers, fire, earthquake, flood, explosion, riots, wars, civil disorder, rebellion or
sabotage or other such occurrences. MD Anderson shall notify the Sponsor concerning its inability to perform and shall make a reasonable effort to fulfill its obligations under this Agreement. Such delay or inability to perform shall not constitute
a breach of this Agreement. 
 10.4 Principal Investigator and Sponsor may be parties to a consulting agreement or other outside agreement to which MD
Anderson is not a party, and Sponsor acknowledges and agrees that MD Anderson has no involvement with or responsibility for any such consulting or outside agreement. 

10.5 Any notice required by this Agreement must be given in writing by personal delivery, overnight delivery, facsimile telecommunication, or certified or
registered mail (return receipt requested), addressed in the case of MD Anderson to: 
  

					
	The University of Texas	  	and to:	  	The University of Texas
	M. D. Anderson Cancer Center	  		  	M. D. Anderson Cancer Center
	Legal Services-Unit 1674	  		  	1515 Holcombe Boulevard
	7007 Bertner Ave	  		  	Office of Sponsored Programs
	Houston, Texas 77030-4009	  		  	Attn: Executive Director
		  		  	Houston, TX 77030

  
 8 

 and in the case of Sponsor to: 
  

					
	Genprex, Inc.	  		  	
	Attn: Chief Executive Officer	  		  	
	6034 Courtyard Drive, Suite 110	  		  	
	Austin, Texas 78738	  	and to:	  	Wilson & Varner, LLP
		  		  	7004 Bee Cave Road
		  		  	Bldg 1, Suite 100
		  		  	Austin, Texas 78746

 All notices will be effective and will be deemed delivered (i) if by personal delivery, delivery service or courier, on
the date of delivery; and (ii) if by certified or registered mail, on the earlier of the date indicated on the return receipt or seven (7) days after deposit in the mail. Either Party may change their notice address by written notice to
the other. 
  

	10.6	This Agreement shall be construed and enforced in accordance with the laws of the State of Texas. 

 10.7 This
Agreement is subject to, and the parties agree to comply with, all applicable local, state, federal, national and international laws, statutes, rules and regulations, including any applicable Export Controls. Any provision of any law, statute, rule
or regulation that invalidates any provision of this Agreement, that is inconsistent with any provision of this Agreement, or that would cause one or any of the parties hereto to be in violation of law will be deemed to have superseded the terms of
this Agreement. The parties, however, will use all reasonable endeavors to accommodate the terms and intent of this Agreement to the greatest extent possible consistent with the requirements of the law and will negotiate in good faith toward
amendment of this Agreement in such respect. If the parties cannot reach agreement on an appropriate amendment, then this Agreement may be immediately terminated by either party. 

10.8 MD Anderson is an agency of the State of Texas and under the constitution and the laws of the State of Texas possesses certain rights and privileges, is
subject to certain limitations and restrictions, and only has such authority as is granted to it under the constitution and laws of the State of Texas. Notwithstanding any provision hereof, nothing in this Agreement is intended to be, nor will it be
construed to be, a waiver of the sovereign immunity of the State of Texas or a prospective waiver or restriction of any of the rights, remedies, claims, and privileges of the State of Texas. Moreover, notwithstanding the generality or specificity of
any provision hereof, the provisions of this Agreement as they pertain to MD Anderson are enforceable only to the extent authorized by the constitution and laws of the State of Texas; accordingly, to the extent any provision hereof conflicts with
the constitution or laws of the State of Texas or exceeds the right, power or authority of MD Anderson to agree to such provision, then that provision will not be enforceable against MD Anderson or the State of Texas. 

  
 9 

 10.9 English is the official language of this Agreement. Accordingly, all notices, documents and communications
relating to the Agreement, and all dispute resolution proceedings arising under this Agreement must be, in their entirety, in English. 
 IN
WITNESS WHEREOF, MD Anderson and Sponsor hereby enter into this Agreement, effective as of the date first set forth above, and execute two (2) original counterparts. 
  

									
	Sponsor	 		 	MD Anderson
					
	BY	 	/s/ Rodney Varner	 		 	BY:	 	/s/ Jaime Farias
		 	Rodney Varner	 		 		 	 Jaime Farias, MBA

		 	Chief Executive Officer	 		 		 	Assistant Director
		 		 		 		 	Sponsored Programs
			
		 		 	I acknowledge that I have read and understand this Agreement in its entirety:
					
		 	  
	 		 	BY:	 	/s/ Charles Lu
		 		 		 		 	Dr. Charles Lu
		 		 		 		 	Principal Investigator
				
		 		 		 	I acknowledge that I have read and understand this Agreement in its entirety:
					
		 	  
	 		 	BY:	 	/s/ Reza Mehran
		 		 		 		 	Dr. Reza Mehran, Project director,
		 		 		 	Phase I/II Clinical Trial Combining FUS1-Nanoparticles and Erlotinib in Stage IV Lung Cancers

  
 10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00274-of-00352.parquet"}]]